LYEL

Lyell Immunopharma, Inc.

• Seeking Alpha·03/23 20:37

  Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet

• TipRanks·03/23 10:25

  Lyell Immunopharma: Differentiated Dual‑Target CAR‑T Pipeline and Upcoming Clinical Milestones Support Buy Rating and Acquisition Potential

• Reuters·03/16 23:25

  Lyell Immunopharma CFO and Chief Business Officer Smital Shah files Form 3 initial beneficial ownership statement

• TipRanks·03/13 10:40

  Lyell Immunopharma price target raised to $39 from $32 at Lucid Capital

• Reuters·03/12 21:12

  Lyell Immunopharma misses Q4 revenue estimates

• Seeking Alpha·03/12 21:02

  Lyell Immunopharma reports Q4 results

• Dow Jones·03/12 20:05

  Press Release: Lyell Immunopharma Reports Q4 and -2-

• Dow Jones·03/12 20:05

  Press Release: Lyell Immunopharma Reports Q4 and -3-

• Dow Jones·03/12 20:05

  Press Release: Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

• TipRanks·03/10 02:09

  Major Investors Double Down on Lyell Immunopharma in Bold New Move

• Dow Jones·03/09 13:05

  Lyell Immunopharma Price Target Announced at $34.00/Share by Citizens

• Dow Jones·03/09 13:05

  Lyell Immunopharma Initiated at Market Outperform by Citizens

• Benzinga·03/09 12:55

  Citizens Initiates Coverage On Lyell Immunopharma with Market Outperform Rating, Announces Price Target of $34

• Dow Jones·03/09 12:21

  Lyell Immunopharma Names Smital Shah Chief Financial, Business Officer

• Benzinga·03/09 12:16

  Lyell Immunopharma Secures Additional $50M From Private Placement After CAR-T Trial Milestone; Appoints Smital Shah As CFO